Literature DB >> 14761913

Are we overtreating rectal cancer: time for another trial?

Peter W G Carne, Heidi Nelson.   

Abstract

Entities:  

Mesh:

Year:  2004        PMID: 14761913     DOI: 10.1245/aso.2004.11.905

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  5 in total

1.  Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery.

Authors:  Samy M AlGizawy; Hoda H Essa; Badawy M Ahmed
Journal:  Oncologist       Date:  2015-06-03

2.  Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base.

Authors:  Richard J Cassidy; Yuan Liu; Kirtesh Patel; Jim Zhong; Conor E Steuer; David A Kooby; Maria C Russell; Theresa W Gillespie; Jerome C Landry
Journal:  Cancer       Date:  2016-10-25       Impact factor: 6.860

3.  Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).

Authors:  Deborah Schrag; Martin Weiser; Leonard Saltz; Harvey Mamon; Marc Gollub; Ethan Basch; Alan Venook; Qian Shi
Journal:  Clin Trials       Date:  2019-01-28       Impact factor: 2.486

4.  Magnetic resonance imaging (MRI)-based indication for neoadjuvant treatment of rectal carcinoma and the surrogate endpoint CRM status.

Authors:  Joachim Strassburg; Theo Junginger; Trong Trinh; Olaf Püttcher; Katja Oberholzer; Richard J Heald; Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2008-07-17       Impact factor: 2.571

5.  Use of Preoperative Magnetic Resonance Imaging to Select Patients with Rectal Cancer for Neoadjuvant Chemoradiation--Interim Analysis of the German OCUM Trial (NCT01325649).

Authors:  Martin E Kreis; R Ruppert; H Ptok; J Strassburg; P Brosi; A Lewin; M R Schön; J Sauer; T Junginger; S Merkel; P Hermanek
Journal:  J Gastrointest Surg       Date:  2015-11-10       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.